Jack Harkness’s acquisition of Furgler Pharmaceuticals

Jack Harkness’s acquisition of Furgler Pharmaceuticals was the turning point that put a major pharmaceutical company under his control. In 1995, as Lenore Furgler’s health declined, she sold him the company at a price described as neither premium nor negligible. The source of his money remained uncertain, but the result was clear: Furgler Gesellschaft became Harkness Pharmaceuticals, the platform for a rapidly expanding business and, later, the distribution of Harkness’s nanobot programme.

The path to the sale

Harkness’s takeover followed years of movement through the company’s ranks. After studying Archaeology and Anthropology at St John’s College, Cambridge, and spending 1978 to 1981 largely out of view, he appeared in Switzerland as Lenore Furgler’s personal assistant. She had recently inherited control of Furgler Gesellschaft, a medium-sized Basel pharmaceutical company. During the 1980s, Harkness gained a seat on its board and responsibility for company strategy. Lenore trusted him, while her three sons reportedly expected to inherit control and remove him. That anticipated handover never came.

By the time of the sale, Harkness had married Mona Jackson, and he and Mona divided their time between Basel, London and Monte Carlo, as well as Cornwall. Lenore’s decision to sell transferred the company to the man already positioned inside its leadership. Although the reported price was not an obvious bargain, it was not considered a premium one either; the account leaves the terms short of a full explanation of how the transaction was financed.

Uncertain financing and decisive control

No one in the account knows for certain where Harkness obtained the purchase money. Rumours connected him to Vladimir Drishkov, a Russian oligarch who headed a mining corporation described as corruptly acquired. Drishkov was shot dead by unidentified assassins a few months after the sale. The timing lends the speculation an ominous edge, but it does not establish that Drishkov financed the acquisition or explain his death. What the narrative does establish is the consequence of the deal: Harkness was in charge, and the company now bore his name.

From takeover to global business

Under Harkness, the company expanded quickly. He opened a dedicated research laboratory in Locarno, where Filippo Crosetti developed a sequence of beauty products. Their success culminated in Elixtris, an anti-ageing cream released in 2009. The product helped Harkness Pharmaceuticals weather the economic downturn and become a major international business. A partnership with Quintagler Industries supplied funds for buyouts of mid-ranking competitors in North America, Europe and Asia, extending the company’s reach beyond its original Swiss base.

That reach later mattered beyond ordinary commercial growth. Crosetti explains that Harkness treated pharmaceuticals as a means of acting against climate change, recruited Astrid Townsend and then Crosetti, and developed a nanobot programme. By the time the plan is exposed, nanobots have been incorporated into products sold by Harkness Pharmaceuticals, including cosmetics and medicines, and into some agricultural products. The acquisition did not itself reveal the full plan, but it gave Harkness control of the corporate machinery through which the programme could be produced and distributed.

The company in patients’ lives

The company’s presence also appears in a more intimate register through Holly Walsh’s treatment. Holly, who has multiple sclerosis, describes receiving experimental Ditrimantelline through an anonymous benefactor she calls Luscinia. She says the drug has brought her symptoms under control and restored her life; Anna confirms that the treatment has been transformative. In Holly’s bathroom, the medicine cartons identify Harkness Pharmaceuticals as the manufacturer, making the company’s products tangible within her daily care.

The funding, however, is not presented as settled fact. Holly suspects that Luscinia may be a Harkness employee diverting company funds to pay for her medication, after a private investigator working for Harkness’s creditors asks about money from the Nightingale account at Credit Suisse. The possibility links corporate finances to a patient’s dependence on treatment, but remains Holly’s fear rather than a confirmed account of the acquisition’s financing or the company’s payment practices. Across these contrasting appearances, the takeover marks Harkness’s ascent from a trusted insider to the owner of a company whose products reach patients and consumers across borders.